Abstract
This data article contains a supplementary figure and validation data relating to the research article entitled “Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes” (Shimizu et al., Clinica Chimica Acta 441, 71–74, 2015), which presents a multiplex real-time polymerase chain reaction method with dual-labeled probes for human P450 2A6 wild-type and whole-gene deletion. Real-time methods have dramatically improved the speed of complex genetic diagnostics compared to conventional assays based on restriction enzyme digestion. Here, we show the basic assay validation data by single and multiplex determinations in comparison with commercial TaqMan copy number assays for P450 2A6.
Keywords: CYP2A6*1, CYP2A6*4, Copy number assays, Real-time PCR, TaqMan, Whole-gene deletion
Specifications table
| Subject area | Biology |
| More specific subject area | Human molecular genetics |
| Type of data | Table, gel image, text file |
| How data was acquired | Applied Biosystems 7300 Real-Time PCR System |
| Data format | Analyzed data, validated with three independent methods. |
| Experimental factors | Human blood drop samples and DNA fractions obtained from 45 Japanese individual subjects. |
| Experimental features | A rapid detection assay of wild-type and whole-gene deletion-type of human P450 2A6 by multiplex real-time polymerase chain reaction and commercially available TaqMan assays for P450 2A6 copy number determinations were validated. |
| Data source location | Showa Pharmaceutical University, Machida, Tokyo, Jc,apan |
| Data accessibility | The data are supplied with this article. |
Value of the data
-
1.
A real-time polymerase chain reaction (PCR) assay for cytochrome P450 2A6 genotyping recently developed [1] was fully validated using a conventional PCR-restriction fragment length polymorphism (RFLP) method (Fig. 1).
-
2.
Aside from the PCR-based methods outlined in this report, commercially available TaqMan assays for copy number determinations (whole-gene deletion P450 2A6*4 genotyping in regions of limited homology) were almost validated (Table 1).
-
3.
Genotyping strategies for P450 2A6 wild-type (P450 2A6*1) and whole-gene deletion (P450 2A6*4) alleles defined here could be combined with highly automated genome-wide association studies, which have limited utility for identifying whole-gene deletions.
-
4.
The dataset that supports the genotyping validations of human P450 2A6 wild-type and whole gene deletion are provided by single and multiplex determinations in comparison with commercial TaqMan copy number assays.
Fig. 1.
A representative gel image for genotyping of human P450 2A6 (P450 2A6*1A, 2A6*1B, and 2A6*4) by PCR-RFLP [2], [3], [4] separated on 2% agarose gel. The PCR products of P450 2A6*1A (1323 bp) and 2A6*1B (1322 bp) with a forward primer named 2A6 B4 (5′-CACCGAAGTGTWCCCTATGCTG-3′) and a reverse primer named 2A6 UTR AS-1 (5′-TGTAAAATGGGCATGAACGCCC-3′) [2], [3], [4] were digested by FokI into fragments of 573, 513, 148, and 89 bp and fragments of 661, 513, and 148 bp, respectively. The PCR products of P450 2A6*4 (1309 bp) were digested by FokI into fragments of 661, 411, 148, and 89 bp.
Table 1.
Comparison of genotyping of P450 2A6 of 45 individuals in a Japanese population by conventional PCR (Fig. 1), multiplex real-time PCR [1], and three positions for TaqMan methods (07545274, 04488984, and 07545275).
| PCR-RFLP, FokI | Multiplex real-time PCR | TaqMan |
PCR-RFLP, FokI | Multiplex real-time PCR | TaqMan |
||||
|---|---|---|---|---|---|---|---|---|---|
| 07545274 | 04488984 | 07545275 | 07545274 | 04488984 | 07545275 | ||||
| *1A/*1A | *1/*1 | 1.8 | 1.9 | 2.4 | *1B/*1B | *1/*1 | 1.8 | 1.9 | 2.2 |
| *1A/*1A | *1/*1 | 2.0 | 1.9 | 2.3 | *1B/*1B | *1/*1 | 1.7 | 2.1 | 2.4 |
| *1A/*1A | *1/*1 | 1.8 | 2.1 | 2.4 | *1B/*1B | *1/*1 | 1.9 | 1.8 | 2.4 |
| *1A/*1A | *1/*1 | 2.0 | 2.0 | 2.0 | *1B/*1B | *1/*1 | 2.2 | 2.0 | 2.5 |
| *1A/*1A | *1/*1 | 2.0 | 2.1 | 2.1 | *1B/*1B | *1/*1 | 2.1 | 1.7 | 2.1 |
| *1A/*1A | *1/*1 | 2.2 | 2.3 | 2.3 | *1B/*1B | *1/*1 | 2.2 | 2.5 | 2.1 |
| *1A/*1B | *1/*1 | 1.8 | 1.6 | 1.7 | *1B/*1B | *1/*1 | 2.5 | 2.8 | 2.3 |
| *1A/*1B | *1/*1 | 1.9 | 2.0 | 2.4 | *1B/*1B | *1/*1 | 2.1 | 2.1 | 2.2 |
| *1A/*1B | *1/*1 | 2.1 | 2.1 | 2.2 | *1B/*1B | *1/*1 | 1.7 | 1.8 | 2.2 |
| *1A/*1B | *1/*1 | 2.2 | 1.8 | 2.4 | *1A/*4 | *1/*4 | 1.1 | 1.0 | 1.2 |
| *1A/*1B | *1/*1 | 1.9 | 1.9 | 2.0 | *1A/*4 | *1/*4 | 1.4 | 1.4 | 1.2 |
| *1A/*1B | *1/*1 | 1.9 | 2.0 | 2.4 | *1A/*4 | *1/*4 | 1.3 | 1.3 | 1.5 |
| *1A/*1B | *1/*1 | 1.8 | 1.9 | 2.2 | *1A/*4 | *1/*4 | 1.0 | 1.2 | 1.0 |
| *1A/*1B | *1/*1 | 1.9 | 2.3 | 2.4 | *1A/*4 | *1/*4 | 1.0 | 1.3 | 1.2 |
| *1A/*1B | *1/*1 | 1.5 | 1.9 | 2.5 | *1B/*4 | *1/*4 | 1.1 | 1.0 | 1.3 |
| *1A/*1B | *1/*1 | 2.1 | 2.0 | 2.5 | *1B/*4 | *1/*4 | 1.2 | 0.9 | 1.4 |
| *1A/*1B | *1/*1 | 2.1 | 2.5 | 1.7 | *1B/*4 | *1/*4 | 1.2 | 1.3 | 1.2 |
| *1A/*1B | *1/*1 | 2.0 | 2.3 | 2.5 | *1B/*4 | *1/*4 | 1.2 | 1.3 | 1.3 |
| *1A/*1B | *1/*1 | 1.9 | 2.3 | 2.5 | *1B/*4 | *1/*4 | 1.0 | 1.2 | 1.1 |
| *1A/*1B | *1/*1 | 2.0 | 2.0 | 2.0 | *1B/*4 | *1/*4 | 1.0 | 1.1 | 1.2 |
| *1A/*1B | *1/*1 | 1.7 | 2.2 | 1.7 | *4/*4 | *4/*4 | 0.1 | 0.1 | 0.1 |
| *1B/*1B | *1/*1 | 0.9 | 1.3 | 1.1 | *4/*4 | *4/*4 | 0.2 | 0.2 | 0.2 |
| *1B/*1B | *1/*1 | 1.6 | 1.9 | 2.2 | |||||
1. Data
Validation of genotyping of human wild-type P450 2A6*1 and whole-gene deletion P450 2A6*4 by both PCR-RFLP and real-time platforms was carried out. One of the 45 subjects (genotyped as P450 2A6*1B/*1B, Table 1) was not matched in term of P450 2A6 copy numbers (around 1) in the current TaqMan analysis.
2. Experimental design, materials and methods
The ethics committee of Showa Pharmaceutical University approved this analysis in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained for experimentation from all subjects. Genotyping of P450 2A6 (P450 2A6*1A, 2A6*1B, and 2A6*4) was carried out by conventional PCR amplification (Fig. 1) as described previously [2], [3], [4]. Blood samples were obtained with puncture needles, lysed, and stabilized [5]. Blood samples from healthy non-smoking Japanese volunteers or DNA fractions extracted separately by the standard protocol from the volunteers׳ buccal cells were used for real-time detection of P450 2A6 wild-type and whole-gene deletion [1]. The samples also underwent TaqMan Copy Number Assays (Hs07545274, Hs04488984, and Hs07545275; ThermoFisher Scientific, Waltham, MA, USA). The P450 2A6 copy numbers in the human genomes were calculated using CopyCaller software according to the manufacturer׳s instructions with designed human RNase P TaqMan Copy Number Reference Assays (4403326; ThermoFisher Scientific) after duplex real-time PCR reactions.
Conflicts of interest
None.
Acknowledgments
This work was supported in part by the Japan Society for the Promotion of Science KAKENHI Grant Number 25460198 and an SRF Grant for Biomedical Research in Japan. We thank Drs. Kazuma Kiyotani, Ren Sawaya, Shotaro Uehara, and Norie Murayama for their support of this work and David Smallbones for English language advice.
Footnotes
Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.dib.2015.10.019.
Appendix A. Supplementary material
Supplementary material
References
- 1.Shimizu M., Sawaya R., Kishimoto I., Yamazaki H. Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes. Clin. Chim. Acta. 2015;441:71–74. doi: 10.1016/j.cca.2014.12.018. [DOI] [PubMed] [Google Scholar]
- 2.Fujieda M., Yamazaki H., Saito T., Kiyotani K., Gyamfi M.A., Sakurai M., Dosaka-Akita H., Sawamura Y., Yokota J., Kunitoh H., Kamataki T. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis. 2004;25:2451–2458. doi: 10.1093/carcin/bgh258. [DOI] [PubMed] [Google Scholar]
- 3.Shimizu M., Kiyotani K., Kunitoh H., Kamataki T., Yamazaki H. Different effects of TERT, TP63, and CYP2A6 polymorphism on individual risk of tobacco-related lung cancer in male Japanese smokers. J. Cancer Ther. 2011;2:690–696. [Google Scholar]
- 4.Shimizu M., Ishii Y., Okubo M., Kunitoh H., Kamataki T., Yamazaki H. Effects of ADH1C, ALDH2, and CYP2A6 polymorphisms on individual risk of tobacco-related lung cancer in male Japanese smokers. J. Cancer Ther. 2013;4:28–35. [Google Scholar]
- 5.Nielsen P.B., Petersen M.S., Ystaas V., Andersen R.V., Hansen K.M., Blaabjerg V., Refstrup M. Sample-to-SNP kit: a reliable, easy and fast tool for the detection of HFE p.H63D and p.C282Y variations associated to hereditary hemochromatosis. Gene. 2012;507:79–84. doi: 10.1016/j.gene.2012.06.020. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary material